Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Drug Discovery
Molecular glue firms advance
by Sarah Braner
June 1, 2024
| A version of this story appeared in
Volume 102, Issue 17
Degron Therapeutics has partnered with Takeda to develop molecular glue degraders that will be used in cancer, inflammation, and neuroscience treatments. The deal centers on Degron’s GlueXplorer platform, which will be used to identify possible degrader candidates. Separately, Monte Rosa Therapeutics, which also develops molecular glue degraders, says it has collected $100 million before expenses from its underwritten public offering. The company says its QuEEN platform uses AI, proteomics, drug libraries, and structural biology to identify candidates and targets.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter